10x Genomics

Sandoz announces nominations to the Board of Directors and leadership change

Retrieved on: 
Tuesday, March 5, 2024

Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.

Key Points: 
  • Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.
  • I am pleased we can propose exceptional people in science and in business for election to the Board of Directors this year.
  • The new Board talent maintains the complementarity of expertise and experience in the areas relevant to Sandoz.
  • The following persons are recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2024:

Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations

Retrieved on: 
Tuesday, January 30, 2024

SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations.

Key Points: 
  • SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations.
  • Shareholders who have incurred losses on their investment in the company are encouraged to contact the firm to learn about potentially recovering their losses.
  • For more details on the investigation, visit https://www.johnsonfistel.com/investigations/10x-genomics
    The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations

Retrieved on: 
Thursday, February 1, 2024

Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations.

Key Points: 
  • Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations.
  • Shareholders who have incurred losses on their investment in the Company are encouraged to contact the firm to learn about potentially recovering their losses.
  • For more details on the investigation, visit:
    The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

10x Genomics Launches Xenium Catalyst Network

Retrieved on: 
Wednesday, December 20, 2023

PLEASANTON, Calif., Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide. The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.

Key Points: 
  • The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.
  • 10x Genomics expects to add more research institutions to the Xenium Catalyst Network in 2024.
  • "K2bio, a novel full service preclinical Contract Research Organization (CRO), welcomes our partnership with 10x Genomics and the Xenium Catalyst Network," said Kieron Jones, CEO at K2bio.
  • "Participating in the 10x Genomics Xenium Catalyst Network will help us deliver state-of-the-art spatial genomics services," stated Michael Heinz, Director of Research Operations at the McDonnell Genome Institute.

Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness

Retrieved on: 
Tuesday, December 19, 2023

PLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a 10x-conducted study using the Chromium Single Cell, Visium Spatial and Xenium In Situ platforms as part of an integrative approach to understand how tumor microenvironment differences influence invasiveness. 

Key Points: 
  • The peer-reviewed publication, which is now available in Nature Communications, refines and builds on work previously posted in bioRxiv in late 2022.
  • The researchers first defined the cellular composition of the sample using Chromium Single Cell Gene Expression Flex (Chromium scFFPE-seq), which yields highly sensitive whole transcriptome data.
  • Lastly, the team used the single cell spatial resolution of Xenium In Situ to more precisely map complex regions of the tumor where multiple cell types were present in very close proximity.
  • Sarah Taylor, Senior Director of Applications at 10x Genomics, said, "This study was only possible due to the complementarity that exists between our platforms.

NanoString Comments on Delaware District Court Verdict

Retrieved on: 
Sunday, November 19, 2023

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty.
  • “We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amended in our post-trial motions and then expect to appeal to the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes.
  • This verdict does not prevent NanoString from continuing to sell GeoMx products anywhere in the world.
  • NanoString remains fully dedicated to enabling scientists to map the universe of biology and ultimately saving patients’ lives.

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

Retrieved on: 
Thursday, December 7, 2023

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

Key Points: 
  • PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.
  • "Our goal is to provide researchers with a highly detailed genetic map of the damage caused in neurodegenerative disorders," said Andrew B. Singleton, Ph.D., NIH CARD director.
  • NIH CARD scientists aim to produce high-quality, standardized and harmonized datasets that can be integrated with other modalities, like long-read DNA sequencing.
  • NIH CARD is a collaborative initiative of the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke.

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Retrieved on: 
Friday, November 17, 2023

PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG). In awarding over $31 million in damages, the jury found that NanoString's GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection willfully infringe all seven asserted patents owned by Prognosys and exclusively licensed to 10x Genomics.

Key Points: 
  • GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents
    PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG ).
  • "In the last six months, three separate courts have found that both NanoString's CosMx and GeoMx products infringe nine separate 10x patents," said Eric Whitaker, Chief Legal Officer at 10x Genomics.
  • "At some point, NanoString must drop the charade that it is 'confident' it does not infringe the 10x patents and the patents are invalid.
  • This ruling is the third time that NanoString has been found to infringe 10x patents in the past six months.

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

Retrieved on: 
Tuesday, November 7, 2023

FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.

Key Points: 
  • FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.
  • Combining MedGenome's expertise in single cell data analysis promises to deliver groundbreaking insights into complex and rare diseases.
  • The 10x Genomics certification highlights MedGenome's expertise in offering single-cell sequencing tools to help researchers accelerate their genomic studies.
  • MedGenome is positioned as the top genomics research service provider in the San Francisco Bay Area.

10x Genomics to Present at the Stephens 25th Annual Conference

Retrieved on: 
Wednesday, November 1, 2023

PLEASANTON, Calif., Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25th Annual Conference on Tuesday, November 14, at 10:00 a.m. Central Time.

Key Points: 
  • PLEASANTON, Calif., Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25th Annual Conference on Tuesday, November 14, at 10:00 a.m. Central Time.
  • Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/ .
  • The webcast will be archived and available for replay for at least 45 days after the event.